Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.37 |
| ▸ | NPY4R | P50391 | 4/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909025 | 0.92 | FAP (0.37) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22694922 | 0.92 | FAP (0.37) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22267878 | 0.92 | FAP (0.37) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24780979 | 0.89 | NMT1 (0.44) | NPY4RNPY5RNPY1RNPY2RNMT2 | |
| SCHEMBL18932364 | 0.89 | FAP (0.38) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29308956 | 0.89 | NPY5R (0.40) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19170785 | 0.88 | SIRT5 (0.33) | FAPFURIN | |
| SCHEMBL26058204 | 0.88 | FAP (0.37) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL25094826 | 0.88 | FAP (0.37) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL23256221 | 0.88 | NPY5R (0.38) | FAPNPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | FAP 4279/4885NPY4R 4779/4885NPY5R 4707/4885 |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | FAP 1009/4885NPY4R 4459/4885NPY5R 4578/4885 |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | FAP 696/4885NPY4R 505/4885NPY5R 461/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | FAP 696/4885NPY4R 505/4885NPY5R 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.